Evaluating dopamine reward pathway in ADHD: clinical implications.

CONTEXT Attention-deficit/hyperactivity disorder (ADHD)--characterized by symptoms of inattention and hyperactivity-impulsivity--is the most prevalent childhood psychiatric disorder that frequently persists into adulthood, and there is increasing evidence of reward-motivation deficits in this disorder. OBJECTIVE To evaluate biological bases that might underlie a reward/motivation deficit by imaging key components of the brain dopamine reward pathway (mesoaccumbens). DESIGN, SETTING, AND PARTICIPANTS We used positron emission tomography to measure dopamine synaptic markers (transporters and D(2)/D(3) receptors) in 53 nonmedicated adults with ADHD and 44 healthy controls between 2001-2009 at Brookhaven National Laboratory. MAIN OUTCOME MEASURES We measured specific binding of positron emission tomographic radioligands for dopamine transporters (DAT) using [(11)C]cocaine and for D(2)/D(3) receptors using [(11)C]raclopride, quantified as binding potential (distribution volume ratio -1). RESULTS For both ligands, statistical parametric mapping showed that specific binding was lower in ADHD than in controls (threshold for significance set at P < .005) in regions of the dopamine reward pathway in the left side of the brain. Region-of-interest analyses corroborated these findings. The mean (95% confidence interval [CI] of mean difference) for DAT in the nucleus accumbens for controls was 0.71 vs 0.63 for those with ADHD (95% CI, 0.03-0.13, P = .004) and in the midbrain for controls was 0.16 vs 0.09 for those with ADHD (95% CI, 0.03-0.12; P < or = .001); for D(2)/D(3) receptors, the mean accumbens for controls was 2.85 vs 2.68 for those with ADHD (95% CI, 0.06-0.30, P = .004); and in the midbrain, it was for controls 0.28 vs 0.18 for those with ADHD (95% CI, 0.02-0.17, P = .01). The analysis also corroborated differences in the left caudate: the mean DAT for controls was 0.66 vs 0.53 for those with ADHD (95% CI, 0.04-0.22; P = .003) and the mean D(2)/D(3) for controls was 2.80 vs 2.47 for those with ADHD (95% CI, 0.10-0.56; P = .005) and differences in D(2)/D(3) in the hypothalamic region, with controls having a mean of 0.12 vs 0.05 for those with ADHD (95% CI, 0.02-0.12; P = .004). Ratings of attention correlated with D(2)/D(3) in the accumbens (r = 0.35; 95% CI, 0.15-0.52; P = .001), midbrain (r = 0.35; 95% CI, 0.14-0.52; P = .001), caudate (r = 0.32; 95% CI, 0.11-0.50; P = .003), and hypothalamic (r = 0.31; CI, 0.10-0.49; P = .003) regions and with DAT in the midbrain (r = 0.37; 95% CI, 0.16-0.53; P < or = .001). CONCLUSION A reduction in dopamine synaptic markers associated with symptoms of inattention was shown in the dopamine reward pathway of participants with ADHD.

[1]  S. Pliszka,et al.  Attention‐Deficit‐Hyperactivity Disorder: An Update , 2009, Pharmacotherapy.

[2]  D. Young,et al.  Attention Deficit Hyperactivity Disorder: A Rasch Analysis of the SWAN Rating Scale , 2009, Child psychiatry and human development.

[3]  Nikos Makris,et al.  Subcortical differences among youths with attention-deficit/hyperactivity disorder compared to those with bipolar disorder with and without attention-deficit/hyperactivity disorder. , 2009, Journal of child and adolescent psychopharmacology.

[4]  K. Lesch,et al.  Neural Hyporesponsiveness and Hyperresponsiveness During Immediate and Delayed Reward Processing in Adult Attention-Deficit/Hyperactivity Disorder , 2009, Biological Psychiatry.

[5]  Anqi Qiu,et al.  Basal ganglia volume and shape in children with attention deficit hyperactivity disorder. , 2009, The American journal of psychiatry.

[6]  J. Wickens,et al.  Behavioral and Brain Functions Origins of Altered Reinforcement Effects in Adhd , 2022 .

[7]  S. Mitrani‐Rosenbaum,et al.  Attention deficit hyperactivity disorder in obese melanocortin‐4‐receptor (MC4R) deficient subjects: A newly described expression of MC4R deficiency , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[8]  S. Cortese,et al.  Alertness and feeding behaviors in ADHD: does the hypocretin/orexin system play a role? , 2008, Medical hypotheses.

[9]  J. Wickens,et al.  Research review: dopamine transfer deficit: a neurobiological theory of altered reinforcement mechanisms in ADHD. , 2008, Journal of child psychology and psychiatry, and allied disciplines.

[10]  K. Lapane,et al.  Overweight in Children and Adolescents in Relation to Attention-Deficit/Hyperactivity Disorder: Results From a National Sample , 2008, Pediatrics.

[11]  Egidio Barbi,et al.  Chronic lung disease after premature birth. , 2008, The New England journal of medicine.

[12]  S. Stanojevic,et al.  Reference ranges for spirometry across all ages: a new approach. , 2008, American journal of respiratory and critical care medicine.

[13]  Michael Bauer,et al.  Reward anticipation and outcomes in adult males with attention-deficit/hyperactivity disorder , 2008, NeuroImage.

[14]  S. Rauch,et al.  Further Evidence of Dopamine Transporter Dysregulation in ADHD: A Controlled PET Imaging Study Using Altropane , 2007, Biological Psychiatry.

[15]  W. Iacono,et al.  Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. , 2007, Archives of general psychiatry.

[16]  Stefano Guerra,et al.  Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study , 2007, The Lancet.

[17]  Frank Telang,et al.  Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. , 2007, Archives of general psychiatry.

[18]  R. Wightman,et al.  Associative learning mediates dynamic shifts in dopamine signaling in the nucleus accumbens , 2007, Nature Neuroscience.

[19]  Young T. Hong,et al.  Nucleus Accumbens D2/3 Receptors Predict Trait Impulsivity and Cocaine Reinforcement , 2007, Science.

[20]  B. J. Casey,et al.  Etiologic Subtypes of Attention-Deficit/Hyperactivity Disorder: Brain Imaging, Molecular Genetic and Environmental Factors and the Dopamine Hypothesis , 2007, Neuropsychology Review.

[21]  Nora D. Volkow,et al.  Brain dopamine transporter levels in treatment and drug naïve adults with ADHD , 2007, NeuroImage.

[22]  P. Auinger,et al.  Exposures to Environmental Toxicants and Attention Deficit Hyperactivity Disorder in U.S. Children , 2006, Environmental health perspectives.

[23]  T. Robbins,et al.  Behavioral models of impulsivity in relation to ADHD: Translation between clinical and preclinical studies , 2006, Clinical psychology review.

[24]  S. Cortese,et al.  Sleep and alertness in children with attention-deficit/hyperactivity disorder: a systematic review of the literature. , 2006, Sleep.

[25]  Nicole M Dudukovic,et al.  Altered neural substrates of cognitive control in childhood ADHD: evidence from functional magnetic resonance imaging. , 2005, The American journal of psychiatry.

[26]  Edmund J. S. Sonuga-Barke,et al.  Causal Models of Attention-Deficit/Hyperactivity Disorder: From Common Simple Deficits to Multiple Developmental Pathways , 2005, Biological Psychiatry.

[27]  Mehdi Farshbaf,et al.  Rodent Models of Attention-Deficit/Hyperactivity Disorder , 2005, Biological Psychiatry.

[28]  Jaap Oosterlaan,et al.  The impact of reinforcement contingencies on AD/HD: a review and theoretical appraisal. , 2005, Clinical psychology review.

[29]  Christer Halldin,et al.  Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity , 2005, Biological Psychiatry.

[30]  Albert Gjedde,et al.  Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. , 2005, International review of neurobiology.

[31]  Wei Li,et al.  Larger deficits in brain networks for response inhibition than for visual selective attention in attention deficit hyperactivity disorder (ADHD). , 2005, Journal of child psychology and psychiatry, and allied disciplines.

[32]  J. Swanson,et al.  Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. , 2004, The American journal of psychiatry.

[33]  Albert Gjedde,et al.  ADHD: increased dopamine receptor availability linked to attention deficit and low neonatal cerebral blood flow. , 2004, Developmental medicine and child neurology.

[34]  R. Barkley.  Adolescents with Attention-Deficit/Hyperactivity Disorder: An Overview of Empirically Based Treatments , 2004, Journal of psychiatric practice.

[35]  E. Sonuga-Barke,et al.  The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics , 2003, Neuroscience & Biobehavioral Reviews.

[36]  E. Baraldi,et al.  Flow limitation in infants with bronchopulmonary dysplasia and respiratory function at school age , 2003, The Lancet.

[37]  R. Wise.  Brain Reward Circuitry Insights from Unsensed Incentives , 2002, Neuron.

[38]  A. Gjedde,et al.  Methylphenidate‐Evoked Potentiation of Extracellular Dopamine in the Brain of Adolescents with Premature Birth , 2002, Annals of the New York Academy of Sciences.

[39]  J. Stocks,et al.  Sex-specific prediction equations for Vmax(FRC) in infancy: a multicenter collaborative study. , 2002, American journal of respiratory and critical care medicine.

[40]  John P Seibyl,et al.  Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. , 2002, The American journal of psychiatry.

[41]  N. Zahniser,et al.  Chronic and acute regulation of Na+/Cl- -dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. , 2001, Pharmacology & therapeutics.

[42]  M. Posner,et al.  Genes and attention-deficit hyperactivity disorder , 2001, Clinical Neuroscience Research.

[43]  Alan C. Evans,et al.  Quantitative brain magnetic resonance imaging in girls with attention-deficit/hyperactivity disorder. , 2001, Archives of general psychiatry.

[44]  J L Lancaster,et al.  Automated Talairach Atlas labels for functional brain mapping , 2000, Human brain mapping.

[45]  J. Ferguson,et al.  National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD) , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[46]  M. Ernst,et al.  High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. , 1999, The American journal of psychiatry.

[47]  J. Joyce,et al.  Distribution of Dopamine D3 Receptor Expressing Neurons in the Human Forebrain: Comparison with D2 Receptor Expressing Neurons , 1999, Neuropsychopharmacology.

[48]  J. King,et al.  Attention-deficit hyperactivity disorder and the stress response , 1998, Biological Psychiatry.

[49]  C. Conners,et al.  Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. , 1998, The Journal of clinical psychiatry.

[50]  P. Renshaw,et al.  Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls , 1997, Neurology.

[51]  S. Kollins,et al.  Experimental analysis of childhood psychopathology: A laboratory matching analysis of the behavior of children diagnosed with Attention-Deficit Hyperactivity Disorder (ADHD) , 1997 .

[52]  E. Baraldi,et al.  Pulmonary function until two years of life in infants with bronchopulmonary dysplasia. , 1997, American journal of respiratory and critical care medicine.

[53]  J. Rapoport,et al.  Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. , 1996, Archives of general psychiatry.

[54]  J S Fowler,et al.  Carbon-11-cocaine binding compared at subpharmacological and pharmacological doses: a PET study. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  J S Fowler,et al.  Sensitivity of striatal [11C]cocaine binding to decreases in synaptic dopamine , 1995, Synapse.

[56]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[57]  J S Fowler,et al.  Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  Larry B. Silver,et al.  Attention Deficit Hyperactivity Disorder. A Handbook for Diagnosis and Treatment , 1991 .

[59]  Oral complications of cancer therapies: diagnosis, prevention, and treatment. The National Institutes of Health Consensus Development Conference Statement. , 1991, Oncology.

[60]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[61]  Bernard Bendriem,et al.  Mapping cocaine binding sites in human and baboon brain in vivo , 1989, Synapse.

[62]  R. Wise,et al.  Brain dopamine and reward. , 1989, Annual review of psychology.

[63]  Harold C. Sox,et al.  National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision‐making , 1988 .

[64]  ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY: A REPLY , 1988 .

[65]  R. Barkley.  Attention deficit disorder with hyperactivity. , 1988 .

[66]  W. F. Caul,et al.  Attention deficit disorder with hyperactivity: a specific hypothesis of reward dysfunction. , 1987, Journal of the American Academy of Child and Adolescent Psychiatry.